TARSUS PHARMACEUTICALS, INC. Costs and Expenses
TARSUS PHARMACEUTICALS, INC. (TARS) reported Costs and Expenses of $193.82 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2026-06-30 was $193.82M, a 55.25% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2026-03-31 was $168.18M, a 60.76% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2025-12-31 was $159.64M, a 75.76% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2025-09-30 was $133.23M, a 81.80% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. costs and expenses for fiscal 2025 was $522.33M, a 72.09% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. costs and expenses for fiscal 2024 was $303.52M, a 88.99% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. costs and expenses for fiscal 2023 was $160.60M, a 81.42% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. costs and expenses for fiscal 2022 was $88.53M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $193.82M 10-Q · filed 2026-08-06 | $362.00M 10-Q · filed 2026-08-06 | $521.64M derived: sum of 3 quarters · filed 2026-08-06 | $654.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $168.18M 10-Q · filed 2026-05-06 | $327.82M derived: sum of 2 quarters · filed 2026-05-06 | $461.05M derived: sum of 3 quarters · filed 2026-05-06 | $585.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $159.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $292.87M derived: sum of 2 quarters · filed 2026-02-23 | $417.71M derived: sum of 3 quarters · filed 2026-08-06 | $522.33M 10-K · filed 2026-02-23 |
| 2025-09-30 | $133.23M 10-Q · filed 2025-11-04 | $258.07M derived: sum of 2 quarters · filed 2026-08-06 | $362.69M 10-Q · filed 2025-11-04 | $453.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $124.84M 10-Q · filed 2026-08-06 | $229.46M 10-Q · filed 2026-08-06 | $320.29M derived: sum of 3 quarters · filed 2026-08-06 | $393.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $104.61M 10-Q · filed 2026-05-06 | $195.44M derived: sum of 2 quarters · filed 2026-05-06 | $268.72M derived: sum of 3 quarters · filed 2026-05-06 | $342.84M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $90.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $164.11M derived: sum of 2 quarters · filed 2026-02-23 | $238.22M derived: sum of 3 quarters · filed 2026-02-23 | $303.52M 10-K · filed 2026-02-23 |
| 2024-09-30 | $73.28M 10-Q · filed 2025-11-04 | $147.40M derived: sum of 2 quarters · filed 2025-11-04 | $212.69M 10-Q · filed 2025-11-04 | $270.22M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $74.11M 10-Q · filed 2025-08-06 | $139.41M 10-Q · filed 2025-08-06 | $196.94M derived: sum of 3 quarters · filed 2026-02-23 | $239.75M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $65.30M 10-Q · filed 2025-05-01 | $122.82M derived: sum of 2 quarters · filed 2026-02-23 | $165.63M derived: sum of 3 quarters · filed 2026-02-23 | $198.45M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $57.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $100.33M derived: sum of 2 quarters · filed 2026-02-23 | $133.15M derived: sum of 3 quarters · filed 2026-02-23 | $160.60M 10-K · filed 2026-02-23 |
| 2023-09-30 | $42.81M 10-Q · filed 2024-11-13 | $75.63M derived: sum of 2 quarters · filed 2024-11-13 | $103.08M 10-Q · filed 2024-11-13 | $128.14M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $32.82M 10-Q · filed 2024-08-08 | $60.27M 10-Q · filed 2024-08-08 | $85.33M derived: sum of 3 quarters · filed 2025-02-25 | $108.24M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $27.45M 10-Q · filed 2024-05-08 | $52.51M derived: sum of 2 quarters · filed 2025-02-25 | $75.42M derived: sum of 3 quarters · filed 2025-02-25 | $95.92M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $25.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $47.97M derived: sum of 2 quarters · filed 2025-02-25 | $68.47M derived: sum of 3 quarters · filed 2025-02-25 | $88.53M 10-K · filed 2025-02-25 |
| 2022-09-30 | $22.91M 10-Q · filed 2023-11-09 | $43.41M derived: sum of 2 quarters · filed 2023-11-09 | $63.47M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $20.50M 10-Q · filed 2023-08-10 | $40.56M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $20.06M 10-Q · filed 2023-05-09 | |||
| 2021-09-30 | $16.95M 10-Q · filed 2022-11-09 | $54.40M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |